135 related articles for article (PubMed ID: 38425251)
21. Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report.
Lehmann M; Hosa H; Bartl T; Tsibulak I; Polterauer S; Pötsch N; Seckl MJ; Marth C
Gynecol Oncol Rep; 2023 Oct; 49():101259. PubMed ID: 37636493
[TBL] [Abstract][Full Text] [Related]
22. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
23. [Pulmonary resection in the management of gestational trophoblastic neoplasia: a clinical study].
Cao Y; Xiang Y; Feng FZ; Wan XR; Yang XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):928-30. PubMed ID: 19134333
[TBL] [Abstract][Full Text] [Related]
24. Evaluation and influence of lung metastasis on patient outcome in gestational trophoblastic neoplasia: A 10-year study at a single institution.
Yu H; Li J; Zhu T; Xue X; Lu X
Eur J Obstet Gynecol Reprod Biol; 2020 Aug; 251():162-166. PubMed ID: 32505789
[TBL] [Abstract][Full Text] [Related]
25. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
26. Case report: Multidrug resistant gestational trophoblastic neoplasia: focus on failure of immunotherapy and success of high-dose chemotherapy.
Enuset A; Duck L; Petre C; Machiels JP; Goffin F
Front Oncol; 2024; 14():1391408. PubMed ID: 38803539
[TBL] [Abstract][Full Text] [Related]
27. [Combination chemotherapy with etoposide and cisplatin for high-risk, chemorefractory and recurrent gestational trophoblastic neoplasia].
Jiang J; Nan FF; Yang XS; Zhang YZ; Wang B; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):595-9. PubMed ID: 17983513
[TBL] [Abstract][Full Text] [Related]
28. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide.
Braga A; Mora P; de Melo AC; Nogueira-Rodrigues A; Amim-Junior J; Rezende-Filho J; Seckl MJ
World J Clin Oncol; 2019 Feb; 10(2):28-37. PubMed ID: 30815369
[TBL] [Abstract][Full Text] [Related]
29. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
30. [Outcome of gestational trophoblastic neoplasia patients with residual lung tumor after completion of treatment].
Yang JJ; Xiang Y; Wan XR; Li JG; Yang XY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):26-8. PubMed ID: 17331417
[TBL] [Abstract][Full Text] [Related]
31. Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study.
Wang X; Cang W; Liu X; Cheng Y; Wan X; Feng F; Ren T; Zhao J; Jiang F; Cheng H; Gu Y; Chen L; Li C; Li X; Yang J; Lu X; Xiang Y
EClinicalMedicine; 2023 May; 59():101974. PubMed ID: 37152364
[TBL] [Abstract][Full Text] [Related]
32. The management of hydatidiform mole using prophylactic chemotherapy and hysterectomy for high-risk patients decreased the incidence of gestational trophoblastic neoplasia in Vietnam: a retrospective observational study.
Yamamoto E; Trinh TD; Sekiya Y; Tamakoshi K; Nguyen XP; Nishino K; Niimi K; Kotani T; Kajiyama H; Shibata K; Le QT; Kikkawa F
Nagoya J Med Sci; 2020 May; 82(2):183-191. PubMed ID: 32581399
[TBL] [Abstract][Full Text] [Related]
33. Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017.
Kong Y; Zong L; Cheng H; Jiang F; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
Cancer Med; 2020 Apr; 9(7):2590-2599. PubMed ID: 32022487
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Clinical Characteristics and Outcomes in 7 Patients with Re-recurrent Gestational Trophoblastic Neoplasia.
Li B; Wan X; Liang Y; Lu B; Lu W
J Reprod Med; 2016 Sep; 61(9-10):494-502. PubMed ID: 30383951
[TBL] [Abstract][Full Text] [Related]
35. Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.
Zhu CC; Liu HY; Wei Y; Shen Z; Qian LL; Song WG; Wang J; Wu DB; Zhang XF; Zhou Y
Taiwan J Obstet Gynecol; 2019 May; 58(3):332-337. PubMed ID: 31122520
[TBL] [Abstract][Full Text] [Related]
36. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.
Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC
BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: A retrospective cohort study.
Kong Y; Yang J; Jiang F; Zhao J; Ren T; Li J; Wang X; Feng F; Wan X; Xiang Y
Gynecol Oncol; 2017 Jul; 146(1):81-86. PubMed ID: 28461032
[TBL] [Abstract][Full Text] [Related]
38. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
39. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients.
Soper JT; Spillman M; Sampson JH; Kirkpatrick JP; Wolf JK; Clarke-Pearson DL
Gynecol Oncol; 2007 Mar; 104(3):691-4. PubMed ID: 17137617
[TBL] [Abstract][Full Text] [Related]
40. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
